Nouscom (Italy)

Recent papers from Nouscom (Italy)

1. Cross-reactive immunity against orthopoxviruses after monkeypox virus infection or smallpox vaccinationInternational Journal of Infectious Diseases · 2026
2. Tissue-specific silencing of synthetic mRNAs by de-targeting elements maps vaccination-competent tissues and allows Cas9 de-immunizationMolecular Therapy · 2026
3. Mutations Targeted by Nous-209 Immunotherapy Occur Early in Lynch Syndrome Carriers’ Precancer Lesions with Microsatellite InstabilityCancer Prevention Research · 2026
4. Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancerNature Communications · 2026
5. Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trialNature Medicine · 2026
6. Neoadjuvant personalized viral vaccine prevents tumor relapse in checkpoint-resistant murine melanoma modelJournal for ImmunoTherapy of Cancer · 2025
7. Use of anti-CTLA4 as a molecular adjuvant to support dose sparing of adenoviral vectored vaccines 2800The Journal of Immunology · 2025
8. NOUS-209 off-the-shelf immunotherapy has the potential to hit primary and metachronous colorectal and urothelial cancer in Lynch syndromeMolecular Cancer Therapeutics · 2025
9. STING-mediated antiviral response: insights into MVA replication control in avian cellsMicrobiology Spectrum · 2025
10. Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancernpj Precision Oncology · 2024
11. Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virusCancer Gene Therapy · 2024
12. Characterization of shared neoantigens in Endometrial Cancer with Microsatellite Instability2024
13. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell ResponsesClinical Cancer Research · 2024
14. Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer VaccineVaccines · 2024
15. Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer VaccineCancer Immunology Research · 2024
16. Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumorsMolecular Therapy Oncology · 2024
17. Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of CancerInternational Journal of Molecular Sciences · 2023
18. The common H232 STING allele shows impaired activities in DNA sensing, susceptibility to viral infection, and in monocyte cell function, while the HAQ variant possesses wild-type propertiesScientific Reports · 2023
19. Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancerFrontiers in Immunology · 2023
20. Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activityJournal for ImmunoTherapy of Cancer · 2023